drugset / Trial / NCT00754702
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of metronomic oral vinorelbine taken three times a week plus daily lapatinib without break, as salvage treatment in patients with metastatic breast cancer.
Timeline
- Start
- 2008-10
- Primary completion
- 2011-03
- Completion
- 2011-03
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | — | Oral |
| Subject | Vinorelbine | Small molecule | 50 mg | Oral |